Results 51 to 60 of about 1,043 (146)

Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice

Virology Journal, 2006
Inhibition of the human cytomegalovirus UL97 kinase by maribavir is thought to be responsible for the antiviral activity of this compound. Some mutations that confer resistance to maribavir map to UL97, however additional mutations that also confer ...
Chou Sunwen, Komazin Gloria, Bidanset Deborah J, Quenelle Debra C, Prichard Mark N, Drach John C, Kern Earl R   +6 more
doaj   +1 more source

Discovery of a Baloxavir‐Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo

Advanced Science, Volume 12, Issue 42, November 13, 2025.
Current herpesvirus treatments targeting the viral DNA polymerase are limited by toxicities and drug resistance. Novel compounds inhibiting the nuclease activity of the herpes simplex virus 1 (HSV‐1) terminase complex, required for viral genome packaging, have been identified.
Sabina Andreu, Kai Tang, Jiahui Zhou, Gabriel Pino‐Peco, Nerea López‐Carrobles, Raquel Bello‐Morales, Daniel Galdo‐Torres, Lina Zhang, Federico Gago, José Antonio López‐Guerrero, Xinyong Liu, Peng Zhan, Luis Menéndez‐Arias   +12 more
wiley   +1 more source

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir

Virology Journal, 2009
The UL97 kinase has been shown to phosphorylate and inactivate the retinoblastoma protein (Rb) and has three consensus Rb-binding motifs that might contribute to this activity.
Chou Sunwen, Hartline Caroll B, Frederick Samuel L, Gill Rachel B, Prichard Mark N   +4 more
doaj   +1 more source

State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1743-1759, November 2025.
ABSTRACT Pediatric rare diseases present unique challenges for drug development due to small patient populations, ethical constraints on clinical trial design, and limited prospectively defined natural history data. Model‐Informed Drug Development (MIDD) has emerged as a powerful paradigm to address these challenges by leveraging quantitative methods ...
Rajesh Krishna, Amitava Mitra, Matthew L. Zierhut, Lilly East, Chandra Durairaj   +4 more
wiley   +1 more source

The Cytomegalovirus Protein Kinase pUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting

Microorganisms, 2020
Human cytomegalovirus (HCMV) expresses a variety of viral regulatory proteins that undergo close interaction with host factors including viral-cellular multiprotein complexes.
Mirjam Steingruber, Manfred Marschall
doaj   +1 more source

Current Progress in Targeting Human Cytomegalovirus Infection

iLABMED, Volume 3, Issue 3, Page 303-311, September 2025.
This review highlights recent advances in the mechanisms by which human cytomegalovirus (HCMV) maintains its genome in infected cells, as well as the cellular factors and viral antigens that modulate viral reactivation, which reveal potential targets for addressing HCMV infection.
Yonggang Pei, Jun Chen
wiley   +1 more source

Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Viruses
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality.
Lauren Ogawa, Chelsea Morinishi, Ashrit Multani, Pryce Gaynor, Omer E. Beaird, Christine Pham, Joanna M. Schaenman   +6 more
doaj   +1 more source

A New Next‐Generation Sequencing Approach in Human Cytomegalovirus for the Identification of Antiviral Resistance Mutations and Genotypic Classification

Journal of Medical Virology, Volume 97, Issue 8, August 2025.
ABSTRACT This study introduces a new procedure for antiviral resistance analysis and genetic classification of human cytomegalovirus (HCMV) using next‐generation sequencing (NGS) adapted to existing methodologies, aiming for more targets due to the recent use of new antivirals. It expands the classical investigation of mutations in UL54 and UL97 genes,
Maria Arnedo‐Muñoz, Ignasi Prats‐Méndez, Alejandra Gónzalez‐Sánchez, Maria Carmen Martín, Ariadna Rando‐Segura, Ibai Los Arcos, Patricia Nadal‐Barón, Narcís Saubi, Natalia Mendoza‐Palomar, Marta Bernat‐Sole, Adaia Albasanz‐Puig, Maria Piñana, Cristina Andrés, Susana Melendo‐Pérez, Nieves Larrosa, Andrés Antón, Juliana Esperalba   +16 more
wiley   +1 more source

Maribavir

Drugs in R & D, 2007
Maribavir is a novel benzimidazole riboside compound that is currently in clinical development with ViroPharma for the prevention of cytomegalovirus (CMV) infections in transplant patients. Maribavir is thought to inhibit viral DNA assembly and inhibit egress of viral capsids from infected cell nuclei. This mechanism is different to other available CMV
openaire   +2 more sources

COMPASSIONATE USE OF MARIBAVIR FOR TREATMENT OF RESISTANT CMV INFECTION IN A PEDIATRIC PATIENT UNDERGOING BMT

Brazilian Journal of Infectious Diseases
Introduction: Cytomegalovirus (CMV) infection is one of the main infectious complications in patients undergoing hematopoietic stem cell transplant (BMT), and is associated with significant morbidity and mortality.
Leticia Leite Batista, Jacqueline das Graças Ferreira de Oliveira, Ana Karine Vieira, Gustavo Machado Teixeira, Carolina Lins Rodrigues   +4 more
doaj   +1 more source